What Is SS-31?

Overview

SS-31, also known by the research names elamipretide and MTP-131, is a synthetic aromatic-cationic tetrapeptide belonging to the Szeto–Schiller family of mitochondria-protective compounds. What sets it apart in the literature is its ability to accumulate selectively within mitochondria rather than acting on a cell-surface receptor. Researchers study it as a tool for probing mitochondrial structure, energy production, and the cascade of oxidative damage that follows when bioenergetics break down.

How SS-31 Works

The peptide concentrates inside the inner mitochondrial membrane, where it associates with cardiolipin — a signature phospholipid that anchors and organizes the components of the electron transport chain. By binding cardiolipin-rich domains, SS-31 is proposed to help stabilize cristae architecture and preserve the efficiency of electron transfer. In research models this association is linked to improved ATP output, reduced leakage of reactive oxygen species, and resistance to mitochondrial swelling under stress. Because it targets a structural lipid rather than a signaling receptor, its mechanism is distinct from most other studied peptides.

What the Research Explores

• Primary mitochondrial myopathy, including measures of walking distance, fatigue and functional capacity.
• Barth syndrome and other cardiolipin-linked mitochondrial disorders.
• Heart failure and ischemia-reperfusion injury models.
• Kidney ischemic injury and renal mitochondrial protection.
• Age-related decline in skeletal-muscle bioenergetics.

Forms & Handling

SS-31 is generally supplied as a lyophilized powder, commonly in a 10 mg vial for laboratory work. It is reconstituted with bacteriostatic or sterile water and kept refrigerated once placed in solution, with the dry powder stored frozen for longer-term stability. See the dosing protocol below for the reconstitution math expressed in insulin-syringe units.

Safety & Research Notes

SS-31 is an investigational research compound with no approved human or veterinary use and no established safety profile for administration. In clinical-trial settings, monitoring has noted administration-site reactions with subcutaneous routes alongside events such as gastrointestinal symptoms, headache and fatigue; long-term safety remains indication-dependent and unresolved. Everything described here is mechanistic background drawn from the literature, not a usage recommendation.

References

Related Protocols